Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor
摘要:
Following our previous publication describing the biological profiles, we herein describe the structure-activity relationships of a core set of quinoxalines as the hGLP-1 receptor agonists. The most potent and efficacious compounds are 6,7-dichloroquinoxalines bearing an alkyl sulfonyl group at the C-2 position and a secondary alkyl amino group at the C-3 position. These findings serve as a valuable starting point for the discovery of more drug-like small molecule agonists for the hGLP-1 receptor. (C) Elsevier Ltd. All rights reserved.
Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor
摘要:
Following our previous publication describing the biological profiles, we herein describe the structure-activity relationships of a core set of quinoxalines as the hGLP-1 receptor agonists. The most potent and efficacious compounds are 6,7-dichloroquinoxalines bearing an alkyl sulfonyl group at the C-2 position and a secondary alkyl amino group at the C-3 position. These findings serve as a valuable starting point for the discovery of more drug-like small molecule agonists for the hGLP-1 receptor. (C) Elsevier Ltd. All rights reserved.
Novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions and methods for the treatment and/or prevention of disorders and diseases wherein an activation of the human GLP-1 receptor is beneficial, especially metabolic disorders such as IGT, Type 1 diabetes, Type 2 diabetes and obesity.
[EN] NON-PEPTIDE GLP-1 AGONISTS<br/>[FR] AGONISTES NON PEPTIDIQUES DE GLP-1
申请人:NOVO NORDISK AS
公开号:WO2000042026A1
公开(公告)日:2000-07-20
Novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions and methods for the treatment and/or prevention of disorders and diseases wherein an activation of the human GLP-1 receptor is beneficial, especially metabolic disorders such as IGT, Type 1 diabetes, Type 2 diabetes and obesity.
Metal-Free Addition of Alkyl Bromides to Access 3,3-Disubstituted Quinoxalinones Enabled by Visible-Light Photoredox Catalysis
作者:Jennie Liao、David N. Hunter、Ugochinyere Nancy Oloyede、Joseph W. McLaughlin、Cheng Wang、Abdellatif El Marrouni
DOI:10.1021/acs.joc.3c01054
日期:2023.8.18
A metal-free addition of unactivated alkyl bromides to quinoxalin-2(1H)-ones is described. This method enables the construction of valuable 3,3-disubstituted dihydroquinoxalin-2(1H)-ones bearing quaternary carbon centers under mild, visible-light photoredox catalysis. High functional group tolerance is observed in both the quinoxalinone and alkyl bromide partners. The ability to scale up this method
描述了未活化的烷基溴与喹喔啉-2(1H)-酮的无金属加成。该方法能够在温和的可见光光氧化还原催化下构建有价值的带有季碳中心的3,3-二取代二氢喹喔啉-2(1 H )-酮。在喹喔啉酮和烷基溴伙伴中观察到高官能团耐受性。在光流条件下证明了该方法的放大能力,以实现克级合成。